Obermeyer Wood Investment Counsel Lllp Sells 1,726 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Obermeyer Wood Investment Counsel Lllp lowered its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 12.5% in the 4th quarter, Holdings Channel reports. The fund owned 12,066 shares of the company’s stock after selling 1,726 shares during the quarter. Obermeyer Wood Investment Counsel Lllp’s holdings in Protagonist Therapeutics were worth $277,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. boosted its stake in Protagonist Therapeutics by 96.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,473 shares of the company’s stock valued at $25,000 after purchasing an additional 723 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in shares of Protagonist Therapeutics by 6.1% in the 3rd quarter. Teacher Retirement System of Texas now owns 12,954 shares of the company’s stock worth $216,000 after buying an additional 740 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its stake in shares of Protagonist Therapeutics by 5.9% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 16,303 shares of the company’s stock worth $272,000 after buying an additional 910 shares during the last quarter. Ameritas Investment Partners Inc. raised its holdings in Protagonist Therapeutics by 27.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,477 shares of the company’s stock worth $124,000 after purchasing an additional 976 shares during the period. Finally, Principal Financial Group Inc. raised its holdings in Protagonist Therapeutics by 7.7% in the 3rd quarter. Principal Financial Group Inc. now owns 14,971 shares of the company’s stock worth $250,000 after purchasing an additional 1,068 shares during the period. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on PTGX. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 target price on shares of Protagonist Therapeutics in a report on Wednesday, February 28th. JPMorgan Chase & Co. raised their price target on Protagonist Therapeutics from $34.00 to $37.00 and gave the company an “overweight” rating in a report on Wednesday, February 28th. Finally, StockNews.com upgraded Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, February 28th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $36.00.

Protagonist Therapeutics Stock Up 0.0 %

PTGX traded up $0.01 on Friday, hitting $25.23. The company had a trading volume of 40,319 shares, compared to its average volume of 705,710. The company has a market cap of $1.47 billion, a PE ratio of -16.93 and a beta of 2.01. Protagonist Therapeutics, Inc. has a 12-month low of $13.72 and a 12-month high of $33.34. The business’s fifty day simple moving average is $28.54 and its 200 day simple moving average is $22.85.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings results on Tuesday, February 27th. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.05 by $0.39. The company had revenue of $60.00 million during the quarter, compared to analysts’ expectations of $60.00 million. On average, analysts anticipate that Protagonist Therapeutics, Inc. will post 1.18 earnings per share for the current fiscal year.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $28.31, for a total transaction of $707,750.00. Following the completion of the transaction, the chief executive officer now owns 549,590 shares in the company, valued at $15,558,892.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Asif Ali sold 14,248 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $32.24, for a total value of $459,355.52. Following the completion of the transaction, the chief financial officer now owns 38,397 shares of the company’s stock, valued at $1,237,919.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Dinesh V. Ph D. Patel sold 25,000 shares of the company’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $28.31, for a total value of $707,750.00. Following the transaction, the chief executive officer now directly owns 549,590 shares in the company, valued at $15,558,892.90. The disclosure for this sale can be found here. Insiders sold 82,223 shares of company stock worth $2,522,342 over the last 90 days. Company insiders own 5.00% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.